Japan · Delayed Price · Currency is JPY Sumitomo Pharma Statistics
Total Valuation
Sumitomo Pharma has a market cap or net worth of JPY 729.03 billion. The enterprise value is 930.66 billion.
| Market Cap | 729.03B |
| Enterprise Value | 930.66B |
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Sumitomo Pharma has 397.29 million shares outstanding.
| Current Share Class | 397.29M |
| Shares Outstanding | 397.29M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 12.62% |
| Float | 183.27M |
Valuation Ratios
The trailing PE ratio is 6.62 and the forward PE ratio is 8.17. Sumitomo Pharma's PEG ratio is 0.34.
| PE Ratio | 6.62 |
| Forward PE | 8.17 |
| PS Ratio | 1.61 |
| PB Ratio | 2.52 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.48 |
| P/OCF Ratio | 13.68 |
| PEG Ratio | 0.34 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.14, with an EV/FCF ratio of 19.76.
| EV / Earnings | 8.45 |
| EV / Sales | 2.05 |
| EV / EBITDA | 7.14 |
| EV / EBIT | 8.56 |
| EV / FCF | 19.76 |
Financial Position
The company has a current ratio of 1.40, with a Debt / Equity ratio of 0.90.
| Current Ratio | 1.40 |
| Quick Ratio | 0.91 |
| Debt / Equity | 0.90 |
| Debt / EBITDA | 1.99 |
| Debt / FCF | 5.50 |
| Interest Coverage | 3.59 |
Financial Efficiency
Return on equity (ROE) is 48.39% and return on invested capital (ROIC) is 22.11%.
| Return on Equity (ROE) | 48.39% |
| Return on Assets (ROA) | 8.12% |
| Return on Invested Capital (ROIC) | 22.11% |
| Return on Capital Employed (ROCE) | 17.95% |
| Weighted Average Cost of Capital (WACC) | 7.42% |
| Revenue Per Employee | 118.32M |
| Profits Per Employee | 28.73M |
| Employee Count | 3,832 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.95 |
Taxes
| Income Tax | -14.97B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +162.89% in the last 52 weeks. The beta is 0.46, so Sumitomo Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +162.89% |
| 50-Day Moving Average | 2,373.21 |
| 200-Day Moving Average | 1,774.71 |
| Relative Strength Index (RSI) | 36.79 |
| Average Volume (20 Days) | 18,806,000 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sumitomo Pharma had revenue of JPY 453.40 billion and earned 110.09 billion in profits. Earnings per share was 277.11.
| Revenue | 453.40B |
| Gross Profit | 268.59B |
| Operating Income | 108.40B |
| Pretax Income | 95.12B |
| Net Income | 110.09B |
| EBITDA | 130.00B |
| EBIT | 108.40B |
| Earnings Per Share (EPS) | 277.11 |
Balance Sheet
The company has 57.32 billion in cash and 258.95 billion in debt, with a net cash position of -201.63 billion or -507.52 per share.
| Cash & Cash Equivalents | 57.32B |
| Total Debt | 258.95B |
| Net Cash | -201.63B |
| Net Cash Per Share | -507.52 |
| Equity (Book Value) | 288.94B |
| Book Value Per Share | 727.28 |
| Working Capital | 84.14B |
Cash Flow
In the last 12 months, operating cash flow was 53.28 billion and capital expenditures -6.19 billion, giving a free cash flow of 47.09 billion.
| Operating Cash Flow | 53.28B |
| Capital Expenditures | -6.19B |
| Free Cash Flow | 47.09B |
| FCF Per Share | 118.53 |
Margins
Gross margin is 59.24%, with operating and profit margins of 23.91% and 24.28%.
| Gross Margin | 59.24% |
| Operating Margin | 23.91% |
| Pretax Margin | 20.98% |
| Profit Margin | 24.28% |
| EBITDA Margin | 28.67% |
| EBIT Margin | 23.91% |
| FCF Margin | 10.39% |
Dividends & Yields
Sumitomo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 0.00% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 15.10% |
| FCF Yield | 6.46% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sumitomo Pharma has an Altman Z-Score of 1.96 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.96 |
| Piotroski F-Score | 5 |